TickerTalks
Browse all tickers →
TickerTalks›$BGM
BGBGM

BGM Group Ltd.

$BGM·$58M·Drug Manufacturers - Specialty & Generic·Healthcare
$0.28+2.2%YTD-92.7%1Y-96.7%
Mentions · last 7 days
2026-07-25: 0 posts2026-07-26: 0 posts2026-07-27: 0 posts2026-07-28: 1 posts2026-07-29: 0 posts2026-07-30: 0 posts2026-07-31: 0 posts10%
Price updated 5h ago·X counts updated 3h ago
BGBGM
$BGMBGM Group Ltd.
$0.28+2.17%1 posts0%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $BGM, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Broken storySelling offAI verdict · as of 2026-07-30

Falling on heavy selling — points lower unless it turns around.

A Chinese TCM/API maker down 97% in 12 months at 0.3% of range — the drug lineup is real, the equity is not.

BGM Group is a Chinese pharmaceutical company making traditional Chinese medicine (TCM) derivatives and active pharmaceutical ingredients (APIs), primarily licorice-based products (Gan Di Xin, Qili). It's a real business with genuine products but the equity has been erased — down 97% over 12 months, sitting at 0.3% of the 52-week range at $0.29 per share.

  • The equity has already been erased — down 92% YTD and 97% over 12 months at 0.3% of the 52-week range and 90% below the 200-day moving average; the market has fully priced whatever is broken here and the tape reflects abandonment.
  • Operating results actually grew YoY — Q1 2025 revenue of $14.3M was up from $12.6M (+14%), so the business is generating some growth; the problem is equity structure and China-ADR risk, not the business.
  • The China-ADR-microcap discount is compounding — $58M market cap on ~$60M annualized revenue with -2% operating margin is essentially half-a-quarter of revenue; where you underwrite either a rerating or a delisting.
  • Structural signals are punishing — 2.8M share tiny float, volume at 4% of 30-day average means the tape is essentially untraded; single-session moves are amplified but no natural buyer base to catalyze a bounce.
  • No news catalyst or scheduled earnings on the calendar — the only news in the sample is a February short-interest note ('down 13.0% in February'), which is stale and directionally unhelpful; nothing in the filings or news feed suggests an imminent catalyst.

No dated earnings event exists in the bundle. The near-term catalysts would need to be either an unscheduled 8-K with a specific corporate-action announcement (buyback, reverse-split, going-private) or a China-ADR sector-flow event; absent one of those, the tape stays sub-$0.30 in essentially no-volume drift. Delisting risk at these levels is a real tail, not just a theoretical one.

What to watch: Any 8-K disclosing a corporate action (buyback, reverse split, going-private) or a delisting notice — the near-term catalysts are structural rather than operational; absent one of those, the tape stays sub-$0.30 in no-volume drift with real delisting risk.

Read the AI verdict + X sentiment for $BGM

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Chinese manufacturer of pharmaceutical active ingredients and traditional Chinese medicine products, primarily serving domestic markets.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - Specialty & Generic sits in its cycle right now — and what that implies for $BGM.

Drug Manufacturers - Specialty & Generic · Healthcare

No material change from last week — animal health revenues under pressure from inflation-driven vet visit deferrals while a securities fraud investigation adds governance overhang; the key debate..

What this means for $BGM

Neutral — Chinese manufacturer of pharmaceutical active ingredients and traditional Chinese medicine products, primarily serving domestic markets; limited read-through from drug manufacturers - specialty & generic macro dynamics to this specific revenue mix.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+20.5%YTD
+54.6%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-2.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-0.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-2.2%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-3.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
3.7Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-3.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
16.4%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY25$14.3M—14.5%-15.6%$-0.01$-4.1M
Q2 FY24$12.6M—11.3%-5.4%$0.05—

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.0%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-16.7%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-90.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatTiny float · 2.8M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.9% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.795-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsMay 143
AI summary

BGM filed a Form 3 on May 14, 2026 reporting initial beneficial ownership for a newly designated director, officer, or 10%+ holder. Body unavailable — excerpt contains only SEC cover-page header.

3New insider — initial holdingsMay 143
AI summary

BGM filed a Form 3 on May 14, 2026 reporting initial beneficial ownership for a newly designated director, officer, or 10%+ holder. Body unavailable — excerpt contains only SEC cover-page header.

3New insider — initial holdingsMay 143
AI summary

BGM filed a Form 3 on May 14, 2026 reporting initial beneficial ownership for a newly designated director, officer, or 10%+ holder. Body unavailable — excerpt contains only SEC cover-page header.

3New insider — initial holdingsMay 143
AI summary

BGM filed a Form 3 on May 14, 2026 reporting initial beneficial ownership for a newly designated director, officer, or 10%+ holder. Body unavailable — excerpt contains only SEC cover-page header.

3New insider — initial holdingsApr 133
+ 9 other (8 6-Ks · 1 20-F) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

BGM Group Ltd. (NASDAQ:BGM) Short Interest Down 13.0% in Februarydefenseworld.net·136d ago

More in Drug Manufacturers - Specialty & Generic

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ZYBT$ETON$BHC$INDV$RGC$BIOVF
Voices on X · last 7 days

No standout posts about $BGM on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport